Allarity Therapeutics, Inc. (NASDAQ:ALLR) Sees Significant Decrease in Short Interest

Allarity Therapeutics, Inc. (NASDAQ:ALLR) saw a large decrease in short interest in August. As of August 31st, there was short interest totalling 19,200 shares, a decrease of 93.6% from the August 15th total of 299,300 shares. Based on an average daily trading volume, of 188,000 shares, the days-to-cover ratio is presently 0.1 days.

Allarity Therapeutics Trading Down 6.9 %

Shares of NASDAQ ALLR traded down $0.26 during mid-day trading on Thursday, reaching $3.52. The company had a trading volume of 72,227 shares, compared to its average volume of 120,113. Allarity Therapeutics has a twelve month low of $2.58 and a twelve month high of $714.00. The stock’s 50 day moving average is $0.25 and its 200-day moving average is $1.96.

Allarity Therapeutics (NASDAQ:ALLR) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.11) earnings per share for the quarter. As a group, sell-side analysts anticipate that Allarity Therapeutics will post -2.6 earnings per share for the current fiscal year.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.